Results of a survey of type-2 diabetes patients across Europe were presented at the European Association for the Study of Diabetes meeting last week.
Data from 5,156 patients showed those who reported any hypoglycaemic event had reduced quality of life and treatment satisfaction.
Researchers said patients’ fear of hypoglycaemia may be directly affecting willingness to intensify treatment and adherence as the disorder progresses.
Researchers Professor Klaus Parhofer said that knowing why the remaining quarter did not suffer reduced quality of life was key to improving care.
The ‘huge problem of compliance’ remains a barrier to improved glycaemic control, he added.